Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. Cooper-DeHoff RM, et al. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. Clin Pharmacol Ther. 2022. PMID: 35152405
There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. .. …
There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M; Clinical Pharmacogenomics Implementation Consortium (CPIC). Wilke RA, et al. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. doi: 10.1038/clpt.2012.57. Epub 2012 May 23. Clin Pharmacol Ther. 2012. PMID: 22617227 Free PMC article.
This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly....
This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The st …